09.04.2015
WILEX AG DE000A11QVV0
DGAP-News: WILEX AG: WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific conferences
DGAP-News: WILEX AG / Key word(s): Conference
WILEX AG: WILEX subsidiary Heidelberg Pharma to present at two
upcoming scientific conferences
09.04.2015 / 14:05
---------------------------------------------------------------------
PRESS RELEASE
WILEX subsidiary Heidelberg Pharma to present at two upcoming scientific
conferences
Munich, Germany, 09 April 2015 - WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE)
today announced that its subsidiary Heidelberg Pharma GmbH will present at
two upcoming scientific conferences.
Antibody/Targeted Drug Conjugates (ATDC 2015)
Professor Andreas Pahl, CSO of Heidelberg Pharma, will give a talk on
"Improvement of the therapeutic index of amanitin-based ADCs" at the ATDC
to be held in Porto, Portugal, on 13-15 April 2015. The talk is scheduled
to take place on Tuesday, 14 April 2015 at 4:15 PM GMT in Session 7: ADC
Development.
Annual Meeting of the American Association for Cancer Research (AACR 2015)
At the AACR in Philadelphia, Pennsylvania, taking place from 18 to 22 April
2015, a poster presentation regarding amanitin-based ADCs will be given by
Dr Jan Anderl, Director Biochemistry and Cell Biology of Heidelberg Pharma,
on Sunday, 19 April 2015, 1:00 PM - 5:00 PM EDT in Section 27. The abstract
is available online on the AACR website: http://www.aacr.org.
About WILEX and Heidelberg Pharma
WILEX AG is a biopharmaceutical company which has a ready for partnering
portfolio of antibody-based diagnostic and therapeutic Phase III product
candidates for the detection and targeted treatment of clear cell renal
cell carcinoma. Research and development focus on the operations of its
subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances
the development of the innovative platform technology for antibody drug
conjugates (ADC technology) and provides pre-clinical drug discovery and
development services. WILEX is listed at the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.
Contact IR/PR support WILEX AG MC Services AG Sylvia Wimmer Katja Arnold (CIRO) Corporate Communications Executive Director Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40 Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022 Grillparzerstr. 10, 81675 Munich, Email: katja.arnold[at]mc- Germany services.eu Business Development Heidelberg Pharma GmbH Dr. Marcel Linssen CBO, Executive Vice President Tel.: +49-(0) 6203 1009-40 Email: m.linssen[at]hdpharma.comThis communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will", "should", "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments. --------------------------------------------------------------------- 09.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: WILEX AG Grillparzerstr. 10 81675 München Germany Phone: +49 (0)89 41 31 38 - 0 Fax: +49 (0)89 41 31 38 - 99 E-mail: [email protected] Internet: www.wilex.com ISIN: DE000A11QVV0 WKN: A11QVV Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 342623 09.04.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
WILEX AG ISIN: DE000A11QVV0 können Sie bei EQS abrufen
Biotechnologie , A11QVV , HPHA , XETR:WL6